Blog

DEEP RESEARCH · LONZA

Lonza: One Lonza and Global CDMO Competition

An investment review centered on the CHI divestment, Vacaville integration, bioconjugates capability, and 2025 growth upgrade

Date: 2025-12-01 · Global CDMO/healthcare analysis · Naver Blog source and attached references

You are responsible for your own investment decisions. This material is research, not a recommendation to buy or sell.

0. Bottom line first

Lonza’s core story is the shift from a diversified healthcare supplier to a purer CDMO. One Lonza, the planned CHI divestment, and the Vacaville integration can support a valuation rerating, but only if large CAPEX converts into utilization and free cash flow.

One Lonza transformationFrom fragmented divisions to integrated CDMO platforms
Integrated Biologics~50% of revenue
Advanced Synthesis~30% of revenue
Specialized Modalities~20% of revenue
CHI salePure-play CDMO focus
The key is whether integration and simplification improve ROIC.

1. Investment thesis

Official fact: The source says Lonza has offset the post-pandemic decline in COVID-related revenue with strong commercial biologics demand. It also states that 2025 sales growth guidance, at constant exchange rates, was raised to 20-21%.

Interpretation: Lonza is moving beyond a simple CMO identity toward an integrated developer, manufacturer, drug-product, and next-modality partner. Selling CHI can reduce the conglomerate discount by making that story cleaner.

2. One Lonza: three platforms

The new structure effective April 1, 2025 consolidates prior divisions into three platforms. For customers, the appeal is a single partner from early development to commercial manufacturing.

~50%

Integrated Biologics

The core cash-generating platform, including mammalian and microbial production, drug-product services, and licensing.

~30%

Advanced Synthesis

A platform combining small molecules and bioconjugates, especially ADC capabilities.

~20%

Specialized Modalities

Future-growth modalities such as cell and gene therapy and mRNA.

3. Vacaville and bioconjugates

Official fact: The source cites the integration of the Vacaville, California site acquired from Roche and Lonza’s moat in bioconjugates, including ADCs, as evidence of differentiation.

Interpretation: Large-scale biologics capacity plus difficult chemistry/biology fusion capabilities can move Lonza away from pure scale competition with Samsung Biologics or WuXi Biologics. But acquisitions and expansions require higher utilization to justify the cost.

4. Financial trend

Metric20202021202220232024
Sales4,5085,4096,2236,7176,574
CORE EBITDA1,3791,6651,9951,9991,908
CORE EBITDA Margin30.6%30.8%32.1%29.8%29.0%
ROIC9.1%10.7%11.4%8.7%8.4%
CAPEX9661,3091,8991,6531,381
Net debt2,813(958)(186)9222,859

Interpretation: Sales and EBITDA grew over the period, but margin and ROIC weakened in 2023-2024. This looks like a phase where the cost of investment and portfolio transition appears before utilization and FCF recovery.

5. Risks and monitoring

  • Timing and valuation of the CHI divestment
  • Utilization ramp at Vacaville and Visp expansions
  • Whether ADC/bioconjugates demand converts into durable long-term contracts
  • Whether Biosecure Act pressure on Chinese CDMOs converts into Lonza orders
  • FCF and ROIC improvement after CAPEX

6. My view

Lonza is already a mature CDMO leader, but the current investment point is redefinition rather than maturity. If CHI divestment and One Lonza work, the company can earn a pure-play CDMO premium. If CAPEX efficiency disappoints and utilization lags, rerating can be delayed.

Sources

Naver original